PERSPECTA

News from every angle

← Back to headlines

ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer

ImmunityBio's stock surged following the EU's approval of ANKTIVA for bladder cancer treatment.

18 Feb, 22:37 — 18 Feb, 22:37
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual51d ago

Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer

Read full article →

Related Stories

Oil Prices Rise After Previous Day's Sharp Drop

just now

Bank of Latvia Warns Abolishing Second Pension Pillar Requires Higher Labor Taxes

52m ago

IGIB ETF Offers Broader Bond Exposure Compared to FIGB

55m ago

Montenegrin Parliamentary Parties Spent Nearly €700,000 Last Year

1h ago